H.C. Wainwright downgraded Fate Therapeutics (NASDAQ: FATE) from Buy to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst PT Change Downgrades

Fate Therapeutics (FATE) PT Raised to $18 at Wells FargoMarch 6, 2018 7:33 AM Fate Therapeutics (FATE) PT Raised to $19 at WedbushMarch 6, 2018 6:40 AM Fate Therapeutics (FATE) PT Raised to $16 at Leerink Partners; 'IPSC Platform Key Value Driver'March 6, 2018 5:27 AM Fate Therapeutics (FATE) PT Raised to $20 at Piper JaffrayMarch 6, 2018 3:31 AM Fate Therapeutics (FATE) PT Raised to $20 at BMO Capital; 'Enthusiasm for Cell Therapies Probably Justified'March 6, 2018 1:13 AM Fate Therapeutics (FATE) Misses Q4 EPS by 5cMarch 5, 2018 4:04 PM Form 8-K FATE THERAPEUTICS INC For: Mar 05March 5, 2018 4:02 PM Fate Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational ProgressMarch 5, 2018 4:01 PM